ERBB2 and neoplasm: For example, expressions of HER2, TROP2, EGFR, EpCAM, and nectin 4 are also observed to some extent in non-malignant cells, however because of their overexpression in tumor cells has made them suitable as target antigens in designing ADCs for the solid tumors and currently approved by the FDA (40–44).